Chordoma
Chordoma | |
ICD-O: | M9370/3 |
---|---|
OMIM | 215400 |
DiseasesDB | 31483 |
eMedicine | med/2992 radio/169 orthoped/49 |
MeSH | D002817 |
WikiDoc Resources for Chordoma |
Articles |
---|
Most recent articles on Chordoma |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Chordoma at Clinical Trials.gov Clinical Trials on Chordoma at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Chordoma
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Directions to Hospitals Treating Chordoma Risk calculators and risk factors for Chordoma
|
Healthcare Provider Resources |
Causes & Risk Factors for Chordoma |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Chordoma is a rare slow-growing malignant neoplasm thought to arise from cellular remnants of the notochord. The evidence for this is the location of the tumors (along the neuraxis), the similar immunohistochemical staining patterns, and the demonstration that notochordal cells are preferentially left behind in the clivus and sacrococcygeal regions when the remainder of the notochord regresses during fetal life.
Chordomas can arise anywhere along the neuraxis. The two most common locations are cranially at the clivus and at the sacrum.
In the United States, the annual incidence of chordoma is approximately 1 in one million.
There are three histological variants of chordoma: classical, chondroid and dedifferentiated. The histological appearance of classical chordoma is of a lobulated tumor composed of groups of cells separated by fibrous septa. The cells have small round nuclei and abundant vacuolated cytoplasm, sometimes described as physaliferous (resembling a spider's web). Chondroid chordomas histologically show features of both chordoma and chondrosarcoma.
Prognosis and treatment
In one study, the 10-year tumor free survival rate for sacral chordoma was 46%.[1] Chondroid chordomas appear to have a more indolent clinical course.
Aggressive surgical resection followed by radiation therapy offers the best chance of long-term control.
There are no drugs currently approved to treat chordoma, however chordoma has been shown to have a limited response to the PDGFR inhibitor Imatinib.[2]
References
- ↑ Fuchs B, Dickey ID, Yaszemski MJ, Inwards CY, Sim FH (2005). "Operative management of sacral chordoma". The Journal of bone and joint surgery. American volume. 87 (10): 2211–6. doi:10.2106/JBJS.D.02693. PMID 16203885.
- ↑ Casali PG, Messina A, Stacchiotti S; et al. (2004). "Imatinib mesylate in chordoma". Cancer. 101 (9): 2086–97. doi:10.1002/cncr.20618. PMID 15372471.
External links
- Chordoma Foundation
- Chordoma Support Group
- Images of Chordoma - mostly radiological (CT and MRI scans), one autopsy image